安罗替尼联合白蛋白结合型紫杉醇三线治疗非小细胞肺癌的临床疗效和安全性  

The clinical efficacy and safety of anlotinib and albumin-bound paclitaxel as the third-line therapy in patients with non-small cell lung cancer

作　　者：赵子龙[1] 张美云[2] 高辉[2] 杜伟[2] 巴雅尔[2] 吕艺华 ZHAO Zilong;ZHANG Meiyun;GAO Hui;DU Wei;BA Yaer;LYU Yihua(Department of Respiratory and Critical Care,the First Affiliated Hospital of Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014010,China;Department of General Oncology,Baotou Tumor Hospital)

机构地区：[1]内蒙古科技大学包头医学院第一附属医院呼吸与危重症科,014010 [2]包头市肿瘤医院肿瘤综合内科

出　　处：《天津医药》2022年第5期539-543,共5页Tianjin Medical Journal

基　　金：白求恩·医学科学研究基金(B19096BT)。

摘　　要：目的探讨安罗替尼联合白蛋白结合型紫杉醇(Nab-P)三线治疗非小细胞肺癌(NSCLC)患者的疗效和安全性。方法选取79例NSCLC患者作为研究对象,按照治疗方案分为对照组(36例)和研究组(43例),对照组采用Nab-P治疗,研究组采用安罗替尼联合Nab-P治疗。观察2组临床疗效,随访记录患者无进展生存期(PFS)、总生存期(OS)及不良反应;同时观察2组治疗前后血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)和糖类抗原125(CA125)水平变化情况。结果2组客观缓解率差异无统计学意义(16.28%vs.8.33%,P>0.05);研究组疾病控制率高于对照组(76.74%vs.52.78%,P<0.05)。2组中位PFS分别为4个月和3个月(P>0.05);中位OS分别为9个月和7个月(P<0.05)。治疗后,2组血清VEGF、CEA和CA125水平较治疗前均降低,且研究组低于对照组(P<0.05)。治疗期间,2组不良反应发生率差异无统计学意义(P>0.05)。结论安罗替尼联合Nab-P三线治疗NSCLC具有较好的疗效,可有效降低血清VEGF、CEA和CA125水平,且安全性较好。Objective To investigate the clinical efficacy and safety of anlotinib and albumin-bound paclitaxel(Nab-P)as the third-line therapy in patients with non-small cell lung cancer(NSCLC).Methods Seventy-nine patients with NSCLC were included in this study.According to the treatment plan,patients were divided into the control group(36 cases)and the study group(43 cases).The control group was treated with Nab-P,and the study group was treated with anlotinib combined with Nab-P.The clinical efficacy,progression free survival(PFS),overall survival(OS)and adverse reactions were observed in the two groups.The serum levels of vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)were observed before and after treatment in the two groups.Results There was no significant difference in objective remission rate(ORR)between the two groups(16.28%vs.8.33%,P>0.05).The disease control rate(DCR)was significantly higher in the study group than that of the control group(76.74%vs.52.78%,P<0.05).The median PFS of the study group and the control group were 4 months and 3 months respectively(P>0.05),and the median OS of the study group and the control group were 9 months and 7 months respectively(P<0.05).After treatment,the serum levels of VEGF,CEA and CA125 were decreased than those of before treatment in the two groups(P<0.05),and the serum levels of VEGF,CEA and CA125 were significantly lower in the study group than those in the control group(P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Anlotinib combined with Nab-P as the third-line treatmenthas has good clinical efficacy in patients with NSCLC,which can effectively reduce serum VEGF,CEA and CA125 levels with good safety.

关 键 词：白蛋白结合型紫杉醇 癌 非小细胞肺 分子靶向治疗 血管内皮生长因子类 癌胚抗原 CA-125抗原 安罗替尼 

分 类 号：R734.2[医药卫生—肿瘤]